8-K
filed June 9, 2026, 5:19 PM ET
ticker AXSM
CIK 0001579428
other
confidence high
sentiment neutral
materiality 0.15
Axsome shareholders elect directors, ratify Deloitte, approve say-on-pay at 2026 annual meeting
Axsome Therapeutics, Inc.
- Mark Saad elected Class II director with 28,675,654 votes for, 10,286,822 withheld.
- Susan Mahony elected Class II director with 29,892,131 votes for, 9,070,345 withheld.
- Ratification of Deloitte & Touche as auditor passed with 43,278,147 votes for (98.9% of votes cast).
- Non-binding advisory vote on executive compensation approved with 37,818,384 votes for (97.5% of votes cast).
- Approximately 85.1% of outstanding shares were represented at the meeting.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Axsome Therapeutics, Inc. shareholders approved Ratification of Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-05 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-05
Exact text from the filing
Proposal 2: Ratification of Appointment of Deloitte & Touche LLP. The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 43,278,147 14,407 484,982 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Axsome Therapeutics, Inc. shareholders approved Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers at the 2026-06-05 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-05
Exact text from the filing
Proposal 3: Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers. The Company's stockholders voted to approve, by non-binding advisory vote, the compensation of the Company's named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 37,818,384 777,937 366,155 4,815,060
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Axsome Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2026-06-05 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-05
Exact text from the filing
Proposal 1: Election of Class II Directors. The Company's stockholders elected the following directors to serve as Class II directors until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The votes regarding the election of the Class II directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Mark Saad 28,675,654 10,286,822 4,815,060 Susan Mahony, Ph.D., MBA 29,892,131 9,070,345 4,815,060
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.